Loading...
•
Sep 30, 2020
Capricor Q3 2020 Earnings Report
Capricor reported a net loss for Q3 2020 and provided a corporate update, highlighting progress in exosome platform technology, Duchenne Muscular Dystrophy program, and CAP-1002 for COVID-19.
Key Takeaways
Capricor Therapeutics reported a net loss of $3.9 million, or $0.20 per share, for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled approximately $35.3 million as of September 30, 2020.
Announced positive preclinical data for multivalent exosome-mRNA vaccine for COVID-19.
Developing a safe, non-toxic exosome formulation capable of delivering functional mRNA in vitro and in vivo.
In discussions with the FDA on next steps for the Duchenne Muscular Dystrophy program.
Patient screening is underway in the randomized, double-blind, placebo-controlled INSPIRE study for CAP-1002 for COVID-19.
Capricor
Capricor
Forward Guidance
The Company expects significant pipeline expansion and will be seeking partnering opportunities in the months ahead to further cement its rebranding.